FY2025 EPS Estimates for Adicet Bio Reduced by HC Wainwright

Adicet Bio, Inc. (NASDAQ:ACET) – Equities research analysts at HC Wainwright cut their FY2025 earnings per share estimates for Adicet Bio in a research report issued to clients and investors on Wednesday, January 21st. HC Wainwright analyst R. Burns now expects that the company will post earnings of ($18.36) per share for the year, down from their prior forecast of ($18.08). HC Wainwright currently has a “Buy” rating and a $50.00 price target on the stock. The consensus estimate for Adicet Bio’s current full-year earnings is ($1.39) per share. HC Wainwright also issued estimates for Adicet Bio’s Q4 2025 earnings at ($3.59) EPS, Q1 2026 earnings at ($2.91) EPS, Q2 2026 earnings at ($3.00) EPS, Q3 2026 earnings at ($3.08) EPS, Q4 2026 earnings at ($3.17) EPS and FY2026 earnings at ($12.17) EPS.

Several other equities research analysts have also recently commented on ACET. Canaccord Genuity Group set a $18.00 target price on Adicet Bio and gave the company a “buy” rating in a research note on Tuesday, January 6th. Wedbush reiterated an “outperform” rating and issued a $80.00 price objective on shares of Adicet Bio in a research report on Thursday, November 6th. Citigroup restated a “market perform” rating on shares of Adicet Bio in a research report on Wednesday, November 19th. Guggenheim lifted their price target on shares of Adicet Bio from $112.00 to $128.00 and gave the stock a “buy” rating in a research report on Wednesday, October 8th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Adicet Bio in a report on Thursday, October 30th. One investment analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, Adicet Bio has an average rating of “Moderate Buy” and an average target price of $69.00.

Adicet Bio Price Performance

Shares of ACET stock opened at $8.40 on Friday. Adicet Bio has a 1 year low of $7.15 and a 1 year high of $17.44. The company has a current ratio of 5.62, a quick ratio of 5.62 and a debt-to-equity ratio of 0.01. The firm’s 50 day moving average is $8.55 and its 200-day moving average is $11.06. The firm has a market capitalization of $80.47 million, a price-to-earnings ratio of -0.42 and a beta of 1.60.

Adicet Bio (NASDAQ:ACET) last issued its quarterly earnings data on Wednesday, November 5th. The company reported ($4.64) EPS for the quarter, missing analysts’ consensus estimates of ($4.16) by ($0.48).

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. FNY Investment Advisers LLC bought a new stake in shares of Adicet Bio in the fourth quarter worth about $51,000. Susquehanna International Group LLP acquired a new position in shares of Adicet Bio in the 3rd quarter valued at approximately $33,000. Squarepoint Ops LLC bought a new stake in Adicet Bio during the 3rd quarter worth approximately $38,000. Virtu Financial LLC acquired a new stake in Adicet Bio during the 3rd quarter worth approximately $65,000. Finally, Vontobel Holding Ltd. lifted its stake in Adicet Bio by 33.3% in the second quarter. Vontobel Holding Ltd. now owns 80,000 shares of the company’s stock valued at $49,000 after buying an additional 20,000 shares in the last quarter. 83.89% of the stock is currently owned by institutional investors.

Adicet Bio Company Profile

Adicet Bio, Inc (NASDAQ: ACET) is a clinical‐stage biotechnology company specializing in the development of off‐the‐shelf, allogeneic gamma delta (γδ) T cell therapies for oncology and autoimmune disorders. The company’s proprietary platform enables the genetic engineering of γδ T cells with chimeric antigen receptors (CARs) and other molecular modifications to enhance tumor targeting, expansion, and persistence. By leveraging the innate tumor-recognition properties of γδ T cells, Adicet seeks to overcome the manufacturing and safety challenges associated with autologous cell therapies.

Adicet’s lead product candidate, ADI-001, is a CAR‐engineered allogeneic γδ T cell therapy directed against CD20 for the treatment of relapsed or refractory B-cell malignancies.